Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FIXER: Infliximab for Proliferative Vitreoretinopathy
NCT04891991Phase 2Completed
- Sponsor
- Cairo University
- Start
- Nov 2021
- Primary completion
- Nov 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial in Proliferative Vitreoretinopathy (PVR) comparing Infliximab group with Standard of care group (2 arms). Primary endpoint: Anatomical success at 9 months. Started Nov 2021; status: completed.
02
Drugs
infliximab
03
Conditions
Proliferative Vitreoretinopathy (PVR)
Beyond the preview
Go deeper on NCT04891991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04891991.